HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Fiander, A. Search for Related Content PubMed Articles by Fiander, A.

Prophylactic human papillomavirus vaccination update

^1. Department of Obstetrics and Gynaecology, Wales College of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN, UK Email: fianderan{at}cf.ac.uk (corresponding author)

Key content:

• Prophylactic human papillomavirus (HPV) vaccination was implemented in the UK in 2008 for girls aged 12–13 years.
  
• There is a ‘catch-up’ programme for girls up to the age of 18 years.
  
• The bivalent vaccine (Cervarix®), covering HPV 16 and 18 was chosen for the first 3 years of the UK vaccination programme.
  
• Surveillance is essential to evaluate long-term effectiveness and answer the remaining questions.
  

Learning objectives:

• To be aware of the implementation of HPV vaccination in the UK.
  
• To be aware of remaining unanswered questions and the need for surveillance.
  
• To understand the importance of key messages for girls being vaccinated against HPV.
  

Ethical issues:

• Will HPV vaccination of girls in the UK be acceptable to everyone?
  
• Have the key public health messages been clearly stated and understood?
  
• Addressing the major burden of HPV-related neoplasia in developing countries is an ethical imperative.
  

Please cite this article as: Fiander A. Prophylactic human papillomavirus vaccination update. The Obstetrician & Gynaecologist 2009;11:133–135.

Keywords anogenital neoplasia / cervical cancer / prophylaxis / HPV vaccination